Axsome Therapeutics (AXSM) Operating Leases (2023 - 2026)
Axsome Therapeutics' Operating Leases history spans 4 years, with the latest figure at $22.4 million for Q1 2026.
- On a quarterly basis, Operating Leases fell 6.36% to $22.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $22.4 million, a 6.36% decrease, with the full-year FY2025 number at $23.2 million, up 283.43% from a year prior.
- Operating Leases hit $22.4 million in Q1 2026 for Axsome Therapeutics, down from $23.2 million in the prior quarter.
- Over the last five years, Operating Leases for AXSM hit a ceiling of $23.9 million in Q1 2025 and a floor of $6.0 million in Q4 2024.
- Historically, Operating Leases has averaged $13.7 million across 4 years, with a median of $7.6 million in 2023.
- Biggest five-year swings in Operating Leases: dropped 16.27% in 2024 and later surged 283.43% in 2025.
- Tracing AXSM's Operating Leases over 4 years: stood at $7.0 million in 2023, then dropped by 14.06% to $6.0 million in 2024, then surged by 283.43% to $23.2 million in 2025, then decreased by 3.44% to $22.4 million in 2026.
- Business Quant data shows Operating Leases for AXSM at $22.4 million in Q1 2026, $23.2 million in Q4 2025, and $23.0 million in Q3 2025.